Albert Mitrani has been Chief Operating Officer, President and board member at Organicell Regenerative Medicine, Inc. since April 2018, and he also is the Chairman of the board, Chief Executive Officer, Secretary and Treasurer at Organicell Regenerative Medicine, Inc. — alternate name Biotech Products since June 24, 2011.
Mr. Mitrani formerly was the Chief Executive Officer, President and Director of Analytical Stem Cell Corp. from April 2014 to May 2015. From February 2012 to March 2014, he was the Chief Executive Officer of Americell Trinidad and the President of ASCAAC LLC — American Stem Cell — from March 2011 to January 2013. Mr. Mitrani was the Chief Executive Officer of American Cellular Center in Quito Ecuador from 2009 through 2012.
In this 2,511 word interview, exclusively in the Wall Street Transcript, Mr. Mitrani explains why investors should look at buying stock in his publicly traded company.
“For several years, we have been doing a lot of research in various areas, specifically around lung diseases, and have collected data, more specifically around lung reparation.
When COVID hit, we came to the realization that through all of our work and expertise around regenerative therapeutics for the lungs, that there could be a potential opportunity for us to make a big difference in the treatment of this virus, particularly for patients with more severe lung injury and illness.”
This particular treatment developed from some core stem cell therapy applications.
“And with this knowledge of stem cells, we transitioned out of autologous stem cells and began searching for a regenerative therapy that would be more consistent. Particularly, something that we would be able to commercialize with reproducible and consistent effects.
Autologous stem cell therapies utilized autologous stem cells derived from the patient’s own blood. When you isolate these cells, the stem cell quality varies from patient to patient. The health of the stem cell population is largely dependent upon the patient’s health status and underlying conditions.
In our search for a better therapeutic source of cells for regenerative therapies, we ultimately focused on perinatal tissue…
However, one component of paracrine factors that we found to be most promising for regenerative therapies were cell-secreted nanoparticles called “exosomes” and extracellular vesicles.
This type of therapy no longer requires the use of stem cells or cells. Our ability to identify and isolate these perinatal-derived exosomes is what really changed the direction of our company.”
Get all the details on this potentially life changing drug discovery by reading the entire 2,511 word interview with Mr. Mitrani, exclusively in the Wall Street Transcript.
Cancer Checkpoint Inhibitors are Enhanced by Aethlon's Hemopurifier Removal of Immunosuppresive Exosomes
July 24, 2019
mRNA Delivery Platform and Novel Azole Class Anti-Fungal Treatment Power Biotech Picks from Dr. Raja
March 27, 2019
Graft Versus Host Treatment Nearing Approval in the US: Is this Biotech Stock for You?
March 29, 2019
Biotech with a $2 Billion Market Cap has a $10 Billion Wet AMD Treatment in Development
April 10, 2019
Ewing Sarcoma Treatment and More Potential Cancer Cures From this San Diego Biotech
October 17, 2019
